Clinical Trial

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

Recruiting
View on ClinicalTrials.gov →
Summary
To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-05.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT06676007
Lead Sponsor Sichuan Provincial People's Hospital
Conditions IgA Nephropathy (IgAN), Early Initial Therapy
Enrollment 200 participants
Start Date 2024-10-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-15